TBX3 Transcription Factor as A potential Biomarker for Colorectal Cancer

Abukhoti, Heba Mustafa (2018) TBX3 Transcription Factor as A potential Biomarker for Colorectal Cancer. Masters thesis, الجامعة الإسلامية بغزة.

This is the latest version of this item.

[img] Text
124628.pdf

Download (2MB)

Abstract

Background: Tbx3, a member of the T-box transcription factors, has been shown to play multiple roles in normal development. Tbx3 expression increases in different types of carcinomas, including breast, cervical, colorectal, ovarian, melanoma, pancreatic, lung, liver, bladder, head and neck. Tbx3 overexpression is mainly associated with cancer cell proliferation and metastasis. Objective: Testing Tbx3 transcription factor as a potential biomarker for colorectal cancer. Methodology: Forty-nine colorectal cancer samples and their non-tumor adjacent tissues were collected from the European Gaza Hospital during the period 2014-2016. Sections were prepared for immunohistochemistry; each sample was prepared and immune-stained by primary anti-Tbx3 and suitable secondary and tertiary antibodies. Tbx3 level was evaluated by pathologists in both cancer and normal samples. Clinicopathological data for each patient were documented. The correlation between Tbx3 levels and the clinicopathological parameters were statistically analysed and reported. To investigate the role of Tbx3 in cisplatin resistance in vitro, Tbx3 in HT-29 cells was knocked down by siTbx3. Western blotting was used to estimate and compare proteins levels of Tbx3 and p38. Results: Tbx3 was found to be non-significantly overexpressed in colorectal cancer tissues in comparison to the corresponding non-tumor tissues. Tbx3 level statistically showed a sensitivity of 55.1%, specificity of 59.2%, and AUC of 0.540 (0.059-0.491) at a cut-off value = 5. Which means,Tbx3 testing can not distinguish between normal and tumor tissues. No significant correlation between Tbx3 level and other colorectal cancer markers such as CEA was noticed. The in vitro results showed that cisplatin treatment upregulates the expression of Tbx3 in HT-29, and knocking down Tbx3 in HT-29 cells enhances the cytotoxic effect of cisplatin. Conclusions: Our data suggested Tbx3 as a potential therapeutic marker for CRC and knocking down Tbx3 might enhance the sensitivity of HT-29 cells to therapeutic treatments. Keywords: Tbx3 protein, Biomarker, CRC, Colorectal

Item Type: Thesis (Masters)
Subjects: Q Science > QE Geology
Depositing User: أ. دارين علي أحمد حمد
Date Deposited: 01 Mar 2021 12:00
Last Modified: 01 Mar 2021 12:00
URI: http://scholar.alaqsa.edu.ps/id/eprint/3924

Available Versions of this Item

Actions (login required)

View Item View Item